Final Program

TUESDAY • MAY 17 325
214 Impact, Survival, Symptoms and Management: US and UK
Patient Perceptions of Living with Idiopathic Pulmonary
Fibrosis/A.-M. Russell, M.B. Scholand, E.A. Snyder, A. Russell, C.
Burdett, A.-M. Doyle, J. Lasky, E. Renzoni, A. Wells, L.A.
Saketkoo, London, United Kingdom, p.A6222
215 The Value of a Systematic Assessment of Medication Use and
Polypharmacy in Patients with IPF/S. Maharaj, P.S. Kolb, N.
Hambly, G. Cox, M.R.J. Kolb, Hamilton, Canada, p.A6223
216 A Multicenter, Prospective, Blinded Comparison of Local
Histopathology and Expert Pathology Panel Diagnoses in
ILD/U. Imtiaz, T. Colby, J.L. Myers, K. Cleveland, S. Edejer, P.
Bianchi, Y. Choi, D. Pankratz, J. Huang, G.C. Kennedy, South San
Francisco, CA, p.A6224
217 Association Between Clinical Characteristics and In-Hospital
Mortality in Patients with Idiopathic Pulmonary Fibrosis/J.
Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA,
p.A6225
218 The Diagnosis of Idiopathic Non-Specific Interstitial
Pneumonia (NSIP): Are International Multidisciplinary Team
Discussions Feasible?/J. Moller, A. Altraja, T. Sjaheim, L.B.
Madsen, F. Rasmussen, E. Bendstrup, Aarhus, Denmark, p.A6226
219 The Clinical Utility of a Genomic Diagnostic Test in
Differentiating Usual Interstitial Pneumonia from Other
Interstitial Lung Disease Pathologies/X. Wu, E.A. Belloli, M.
Rosenbluth, Y. Choi, S. Danese, K.R. Flaherty, F.J. Martinez, New
York, NY, p.A6227
220 Prevalence and Determinants of Frailty in Fibrotic Interstitial
Lung Disease/K.M. Milne, J.M. Kwan, S. Guler, T.A. Winstone, A.
Le, P.G. Wilcox, C.J. Ryerson, Vancouver, Canada, p.A6228
221 Quantitative CT Analysis of Honeycombing Area Predicts
Survival in Idiopathic Pulmonary Fibrosis/H. Nakagawa, Y.
Higami, K. Fukunaga, Y. Kashiwagi, M. Osawa, T. Nagao, E.
Ogawa, Y. Nakano, Otsu, Japan, p.A6229
222 Low Sensitivity of Trans Bronchial Biopsies in Diagnosing
Interstitial Lung Diseases/W. Thijs, R. Snooks, S. Fletcher,
Hoofddorp, Netherlands, p.A6230
223 Validation of a Method for Automatic Detection of Lung
Sounds in Fibrotic Interstitial Lung Disease/G. Sgalla, D.
Nikolic, S.L. Walsh, S. Fletcher, S. Cerri, F. Luppi, M.G. Jones,
D.E. Davies, N. Sverzellati, D. Hansell, A. Barney, L. Richeldi,
Southampton, United Kingdom, p.A6231
224 Optimal Low Dose Computed Tomography Parameters for
Evaluating Interstitial Lung Disease: A Systematic Simulation
Study/L. Fidler, S. Ley, H. Schenk, M. Durand, N. Paul, T.K.
Marras, S. Shapera, S. Mittoo, Toronto, Canada, p.A6232
225 Population Demographics of Patients Diagnosed with
Interstitial Lung Disease with Major Complications: A Study
Involving 14,015 Patients/R. Chandrashekar, M. Konda,
Kalamazoo, MI, p.A6233
C103
POSTER DISCUSSION SESSION
EOSINOPHILS IN COPD AND THE ASTHMA-COPD
OVERLAP SYNDROME: SORTING THROUGH THE
CHAOS OF ACOS
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2010/2012 (West Building, Level 2)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
Chairing: D.D. Sin, MD, Vancouver, Canada
P.G. Woodruff, MD, MPH, San Francisco, CA
M.E. Hardin, MD, Boston, MA
401 Is Blood Eosinophil Count a Predictor of Disease
Worsening After ICS Withdrawal?/H. Watz, H. Magnussen, K.
Tetzlaff, L. Gronke, H. Finnigan, P.M. Calverley, Grosshansdorf,
Germany, p.A6234
402 The Stability of Blood Eosinophils in Stable COPD Patients
and Validity of Using Baseline Eosinophil Values to Determine
Eosinophilia in Epidemiological Studies/E.R.C. Millett, C.E.
Brightling, I. Pavord, R. Russell, M. Bafadhel, Oxford, United
Kingdom, p.A6235
403 The Blood Eosinophil Trajectory of Patients with COPD
Through Stable State, Exacerbation and Recovery/E.R.C.
Millett, C.E. Brightling, I. Pavord, R. Russell, M. Bafadhel, Oxford,
United Kingdom, p.A6236
404 Phenotypic/Genetic Characteristics of COPD, Asthma, and
Asthma-COPD Overlap Syndrome (ACOS) in SPIROMICS and
SARP/X. Li, V.E. Ortega, H. Nadia, S. Christenson, W.C. Moore, H.
Li, R.G. Barr, D.J. Couper, E.A. Hoffman, M.K. Han, R. Kanner, E.
Kleerup, F.J. Martinez, G.A. Hawkins, P.G. Woodruff, E.R.
Bleecker, D.A. Meyers, Winston-Salem, NC, p.A6237
405 Fractional Exhaled Nitric Oxide Levels in Asthma-COPD
Overlap Syndrome: Analysis of the NHANES, 2007-2012/T.
Goto, C.A. Camargo, K. Hasegawa, Boston, MA, p.A6238
406 Blood Eosinophil Levels in COPD Patients in the UK Clinical
Practice Research Datalink (CPRD)/S. Landis, R. Suruki, K.
Bonar, E. Hilton, C. Compton, Uxbridge, United Kingdom, p.A6239
407 Does Eosinophilia and Neutrophil-to-Lymphocyte Ratio Effect
Hospital Re-Admission in Cases of COPD Exacerbation?/M.
Agca, E. Aksoy, D. Duman, I. Ozmen, E. Yildirim, S. Gungor, N.D.
Kocak, U. Akturk, C. Salturk, Z. Karakurt, Istanbul, Turkey, p.A6240
408 Clinical Outcomes and Disease Progression in Patients with
Asthma-COPD Overlap Syndrome/J. Cosentino, H. Zhao, M.E.
Hardin, C.P. Hersh, J.D. Crapo, V. Kim, G. Criner, Philadelphia,
PA, p.A6241
409 Asthma-Like Features and Clinical Course in COPD: An
Analysis from the Hokkaido COPD Cohort Study/M. Suzuki, H.
Makita, S. Konno, K. Shimizu, H. Kimura, M. Nishimura, Sapporo,
Japan, p.A6242
TUESDAY AFTERNOON
ATS 2016 • San Francisco